ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,981 to 4,000 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Total Knee Replacement vs Total Hip Replacement: Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge420 of 746

584 of 929

-6.6 points

-11.3 to -1.8

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Total Knee Replacement vs Total Hip Replacement: Occurrence of Major Bleeding Events8 of 746

16 of 929

-0.6 points

-1.8 to 0.6

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Total Knee Replacement vs Total Hip Replacement: Number of Patients Who Switched to Another Anticoagulant Therapy43 of 746

45 of 929

0.9 points

-1.2 to 3.2

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Total Knee Replacement vs Total Hip Replacement: Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge24 of 746

44 of 929

-1.5 points

-3.4 to 0.4

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Total Knee Replacement vs Total Hip Replacement: Occurrence of Symptomatic Venous Thromboembolic Events19 of 746

5 of 929

2.0 points

0.9 to 3.4

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Total Knee Replacement vs Total Hip Replacement: serious adverse events48 of 746

37 of 929

2.5 points

0.3 to 4.7

1,675NCT01139658

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

SOC Arm vs Enhanced Arm: Number of Participants Accessing Sexual and Reproductive Health Related Prevention Services Within 12 Months214 of 816

297 of 859

-8.3 points

-12.7 to -3.9

1,675NCT04429061

Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ

Generic Best Practices (GBP) vs Tailored Best Practices (TBP): Full COVID-19 Vaccination Status Among Staff467 of 836

471 of 837

-0.4 points

-5.2 to 4.3

1,673NCT04726371

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

Fast-tracked vs Control: Daily Service Denials (Bumps)0 of 111

29 of 1,561

-1.9 points

-2.7 to 1.5

1,672NCT01639443

Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Mortality50 of 846

54 of 826

-0.6 points

-3.0 to 1.7

1,672NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Percentage Seizure-free for 6 Months, or Longer, Measured at 24 Months After Enrollment371 of 846

299 of 826

7.7 points

3.0 to 12.3

1,672NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Task-shifted Arm vs Enhanced Usual Care Arm: Anytime 6-month Seizure-free Interval448 of 846

440 of 826

-0.3 points

-5.1 to 4.5

1,672NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): deaths from any cause50 of 846

54 of 826

-0.6 points

-3.0 to 1.7

1,672NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): serious adverse events33 of 846

25 of 826

0.9 points

-0.9 to 2.7

1,672NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: Severe Mpox Lesions6 of 766

2 of 906

0.6 points

-0.2 to 1.5

1,672NCT05965427

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

Drotrecogin Alfa (Activated) vs Placebo: serious adverse events119 of 833

96 of 833

2.8 points

-0.5 to 6.0

1,666NCT00604214

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): ACT (Artemisinin Combination Therapy) Use Among Untested Participants462 of 836

498 of 827

-5.0 points

-9.7 to -0.2

1,663NCT04428385

Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria

Medtronic CoreValve® System TAVI vs SAVR: deaths from any cause98 of 864

80 of 796

1.3 points

-1.7 to 4.3

1,660NCT01586910

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Medtronic CoreValve® System TAVI vs SAVR: serious adverse events718 of 864

694 of 796

-4.1 points

-7.5 to -0.7

1,660NCT01586910

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin: deaths from any cause1 of 833

0 of 827

0.1 points

-0.4 to 0.7

1,660NCT03354598

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=200"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=200

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01139658-3c9ded75",
        "title": "Total Knee Replacement vs Total Hip Replacement: Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge",
        "summary": "420 of 746 against 584 of 929; risk difference -6.6 points, 95% interval -11.3 to -1.8; NCT01139658, Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA",
        "record": "/library/comparisons/NCT01139658-3c9ded75",
        "nct_id": "NCT01139658",
        "kind": "outcome",
        "participants": 1675,
        "risk_difference": {
          "value": -0.06563025767855546,
          "lower": -0.11266878747343745,
          "upper": -0.018381001566961937
        },
        "group_1": "420 of 746",
        "group_2": "584 of 929",
        "difference": "-6.6 points",
        "interval": "-11.3 to -1.8",
        "trial_title": "Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA"
      },
      {
        "id": "NCT01139658-45ea09d5",
        "title": "Total Knee Replacement vs Total Hip Replacement: Occurrence of Major Bleeding Events",
        "summary": "8 of 746 against 16 of 929; risk difference -0.6 points, 95% interval -1.8 to 0.6; NCT01139658, Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA",
        "record": "/library/comparisons/NCT01139658-45ea09d5",
        "nct_id": "NCT01139658",
        "kind": "outcome",
        "participants": 1675,
        "risk_difference": {
          "value": -0.006498959647001444,
          "lower": -0.01831468389796357,
          "upper": 0.005725361529793914
        },
        "group_1": "8 of 746",
        "group_2": "16 of 929",
        "difference": "-0.6 points",
        "interval": "-1.8 to 0.6",
        "trial_title": "Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=201",
  "request_id": "SggUekqBE9dTTXiq"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?